Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgraded
Go back to Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgraded| Rider Explorations, Inc. (NASDAQ: REPL) | Delayed: 11.69 +0.51 (4.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.18 | 52 Week High | $1.45 | |||
| Open | $10.88 | 52 Week Low | $0.50 | |||
| Day High | $12.23 | P/E | N/A | |||
| Day Low | $10.86 | EPS | $0.00 | |||
| Volume | 1,232,402 | |||||
